Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 -6.91%58 3-Year EPS without NRI Growth Rate is 30.00% as of Jun. 2026, which is 203% above its 10-year median of 9.90. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €7.07 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,536 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 74.87% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 30.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of InnoCan Pharma was 30.00% per year. The lowest was -64.10% per year. And the median was 9.90% per year.
InnoCan Pharma (FRA:IP40) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
InnoCan Pharma 3-Year EPS without NRI Growth Rate Related Terms
FRA:IP40 vs PG, CL, EL: 3-Year EPS without NRI Growth Rate Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma 3-Year EPS without NRI Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's 3-Year EPS without NRI Growth Rate falls into.
InnoCan Pharma 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 30.00% mean?
InnoCan Pharma (FRA:IP40) has a 3-Year EPS without NRI Growth Rate of 30.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for InnoCan Pharma and its competitors. This is 203% above median its historical median of 9.90. According to the industry distribution chart, InnoCan Pharma ranks #386 out of 1536 companies in the Consumer Packaged Goods industry, placing it in the top 25.1%.
Is InnoCan Pharma's 3-Year EPS without NRI Growth Rate too high?
InnoCan Pharma's current 3-Year EPS without NRI Growth Rate of 30.00% is 203% above median its 10-year median of 9.90. The Consumer Packaged Goods industry median 3-Year EPS without NRI Growth Rate is 7.30. InnoCan Pharma's value of 30.00% is 311% above this industry median. Based on the distribution chart, InnoCan Pharma ranks #386 out of 1536 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's 3-Year EPS without NRI Growth Rate compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #386 out of 1536 companies for 3-Year EPS without NRI Growth Rate. This puts InnoCan Pharma in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 7.30. InnoCan Pharma's value of 30.00% is 311% above this benchmark. While the company's 10-year median is 9.90 vs. the industry median of 7.30, InnoCan Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Consumer Packaged Goods company?
The median 3-Year EPS without NRI Growth Rate among Consumer Packaged Goods companies is 7.30, based on 1,536 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current 3-Year EPS without NRI Growth Rate of 30.00% is 311% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median 3-Year EPS without NRI Growth Rate is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current 3-Year EPS without NRI Growth Rate is 30.00%, which is 203% above median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.07, compared to a current price of €1.28 — trading 81.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 30.00%, which is 203% above median its 10-year median of 9.90 and 311% above the Consumer Packaged Goods industry median of 7.30. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current 3-Year EPS without NRI Growth Rate is 30.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.28 is trading 81.9% below its estimated GF Value™ of €7.07.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
3-Year EPS without NRI Growth Rate: 30.00% (203% above median its 10-year median of 9.90)
GF Value™: €7.07 vs. price of €1.28 (81.9% below fair value)
Industry Position: 311% above the Consumer Packaged Goods median (#386 of 1536)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for FRA:IP40
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
